Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Update

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 9,500,000 shares, an increase of 8.1% from the December 15th total of 8,790,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the short-interest ratio is currently 5.7 days. Approximately 7.6% of the company’s shares are sold short.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. RPg Family Wealth Advisory LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at $1,886,000. Segall Bryant & Hamill LLC raised its holdings in Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after acquiring an additional 49,856 shares in the last quarter. Retirement Systems of Alabama raised its holdings in Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock valued at $22,282,000 after acquiring an additional 74,173 shares in the last quarter. Creative Planning raised its holdings in Halozyme Therapeutics by 43.2% in the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after acquiring an additional 11,249 shares in the last quarter. Finally, South Street Advisors LLC acquired a new stake in Halozyme Therapeutics in the third quarter valued at $9,812,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 1.0 %

NASDAQ HALO opened at $54.80 on Tuesday. The stock has a market cap of $6.97 billion, a P/E ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24. The company’s fifty day simple moving average is $49.50 and its 200-day simple moving average is $54.14. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53.

Analyst Ratings Changes

A number of analysts have recently commented on the company. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. HC Wainwright boosted their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.